Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.

Autor: Ceriello A; IRCCS MultiMedica, Via Milanese 300, 20099, Sesto San Giovanni, MI, Italy., Rodbard HW; Endocrine and Metabolic Consultants, 3200 Tower Oaks Blvd., Suite 250, Rockville, MD, 20852, USA., Battelino T; University Medical Center Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Brosius F; University of Arizona College of Medicine, 1501 N. Campbell Ave, Tucson, AZ, 85724-5022, USA., Cosentino F; Cardiology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Solna, Stockholm, Sweden., Green J; Duke University Medical Center, Duke Clinical Research Institute, 200 Morris St, DUMC Box 3850, Durham, NC, 27715, USA., Ji L; Peking University People's Hospital, 11 Xizhimen S St, Xicheng District, Beijing, China., Kellerer M; Marienhospital Stuttgart, Böheimstraße 37, 70199, Stuttgart, Germany., Koob S; PCNA National Office, 613 Williamson Street, Suite 200, Madison, WI, 53703, USA., Kosiborod M; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, 4401 Wornall Rd, Kansas City, MO, 64111, USA.; The George Institute for Global Health and University of New South Wales, Sydney, Australia., Lalic N; University Clinical Center of Serbia, University of Belgrade, Pasterova 2, 11000, Belgrade, Serbia., Marx N; Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany., Nedungadi TP; American Heart Association, 7272 Greenville Avenue, Dallas, TX, 75082, USA., Parkin CG; CGParkin Communications, Inc., 2675 Windmill Pkwy, Suite 2721, Henderson, NV, 89074, USA., Rydén L; Department of Medicine K2, Karolinska Institute, Stockholm, Sweden., Sheu WH; Institute of Molecular and Genomic Medicine, National Research Health Institutes, Zhunan, Miaoli, 350, Taiwan., Standl E; Forschergruppe Diabetes E. V, Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany., Vandvik PO; Institute of Health and Society, University of Oslo, Oslo, Norway., Schnell O; Forschergruppe Diabetes E. V, Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany. oliver.schnell@lrz.uni-muenchen.de.
Jazyk: angličtina
Zdroj: Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Oct 13; Vol. 22 (1), pp. 277. Date of Electronic Publication: 2023 Oct 13.
DOI: 10.1186/s12933-023-01993-3
Abstrakt: In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje